An update on drug–drug interactions associated with proton pump inhibitors

References

• Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008 Dec;10(6):528–534.
   PubMedGoogle Scholar
• Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013 Jan;19(1):25–35.
   PubMed Web of Science ®Google Scholar
• Scarpignato C, Gatta L, Zullo A, et al. Effective and safe proton pump inhibitor therapy in acid-related diseases - a position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016 Nov 9;14(1):179.
   PubMedGoogle Scholar
• Barkun AN, Almadi M, Kuipers EJ, et al. Management of nonvariceal upper gastrointestinal bleeding: guideline recommendations from the international consensus group. Ann Intern Med. 2019 Dec 3;171(11):805–822.
   PubMed Web of Science ®Google Scholar
• Johnson DA, Katz PO, Armstrong D, et al. The safety of appropriate use of over-the-counter proton pump inhibitors: an evidence-based review and Delphi consensus. Drugs. 2017 Apr;77(5):547–561.
   PubMed Web of Science ®Google Scholar
• Patel D, Bertz R, Ren S, et al. A systematic review of gastric acid-reducing agent-mediated drug-drug interactions with orally administered medications. Clin Pharmacokinet. 2020 Apr;59(4):447–462.
   PubMed Web of Science ®Google Scholar
• de Waal T, Rubbens J, Grimm M, et al. Exploring the effect of esomeprazole on gastric and duodenal fluid volumes and absorption of ritonavir. Pharmaceutics. 2020 Jul 17; 12(7):670
   Google Scholar
• El Rouby N, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):447–460.
   PubMed Web of Science ®Google Scholar
• Albengres E, Le Louët H, Tillement JP. Systemic antifungal agents. drug interactions of clinical significance. Drug Saf. 1998 Feb;18(2):83–97.
   PubMed Web of Science ®Google Scholar
• Fotaki N, Klein S. Mechanistic understanding of the effect of PPIs and acidic carbonated beverages on the oral absorption of itraconazole based on absorption modeling with appropriate in vitro data. Mol Pharm. 2013 Nov 4;10(11):4016–4023.
   PubMedGoogle Scholar
• Jaruratanasirikul S, Sriwiriyajan S. Effect of omeprazole on the pharmacokinetics of itraconazole. Eur J Clin Pharmacol. 1998 Apr;54(2):159–161.
   PubMed Web of Science ®Google Scholar
• Abuhelwa AY, Mudge S, Upton RN, et al. Mechanistic assessment of the effect of omeprazole on the in vivo pharmacokinetics of itraconazole in healthy volunteers. Eur J Drug Metab Pharmacokinet. 2019 Apr;44(2):201–215.
   PubMed Web of Science ®Google Scholar
• Hilton JF, Tu D, Seymour L, et al. An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib. Lung Cancer. 2013 Oct;82(1):136–142.
   PubMedGoogle Scholar
• Lindsay J, Mudge S, and Thompson GR 3rd. Effects of food and omeprazole on a novel formulation of super bioavailability itraconazole in healthy subjects. Antimicrob Agents Chemother. 2018;62(12):e01723–18.
   PubMedGoogle Scholar
• Nield B, Larsen SR, van Hal SJ. Clinical experience with new formulation SUBA(R)-itraconazole for prophylaxis in patients undergoing stem cell transplantation or treatment for haematological malignancies. J Antimicrob Chemother. 2019 Oct 1;74(10):3049–3055.
   PubMed Web of Science ®Google Scholar
• Abbotsford J, Foley DA, Goff Z, et al. Clinical experience with SUBA-itraconazole at a tertiary paediatric hospital. J Antimicrob Chemother. 2021 Jan 1;76(1):249–252.
   PubMed Web of Science ®Google Scholar
• Zonios D, Yamazaki H, Murayama N, et al. Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype. J Infect Dis. 2014 Jun 15;209(12):1941–1948.
   PubMed Web of Science ®Google Scholar
• Modak AS, Klyarytska I, Kriviy V, et al. The effect of proton pump inhibitors on the CYP2C19 enzyme activity evaluated by the pantoprazole-(13)C breath test in GERD patients: clinical relevance for personalized medicine. J Breath Res. 2016 Dec 17;10(4):046017.
   PubMed Web of Science ®Google Scholar
• Wood N, Tan K, Purkins L, et al., Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol. 2003;56(1): 56–61.
   PubMedGoogle Scholar
• Blanco Dorado S, Maronas Amigo O, Latorre-Pellicer A, et al. A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations. Br J Clin Pharmacol. 2020 Aug;86(8):1661–1666.
   PubMedGoogle Scholar
• Zvyaga T, Chang SY, Chen C, et al. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19. Drug Metab Dispos. 2012 Sep;40(9):1698–1711.
   PubMedGoogle Scholar
• Yan M, Wu ZF, Tang D, et al. The impact of proton pump inhibitors on the pharmacokinetics of voriconazole in vitro and in vivo. Biomed Pharmacother. 2018 Dec;108:60–64.
   PubMed Web of Science ®Google Scholar
• Huang Q, Liu Q, Yin T, et al. Effect of proton pump inhibitors on voriconazole concentrations in Chinese patients with malignant hematological diseases. Eur J Clin Pharmacol. 2020 Jun;76(6):833–842.
   PubMedGoogle Scholar
• Marsot A, Goirand F, Milesi N, et al. Interaction of thiopental with esomeprazole in critically ill patients. Eur J Clin Pharmacol. 2013 Sep;69(9):1667–1672.
   PubMedGoogle Scholar
• Ashbee HR, Barnes RA, Johnson EM, et al. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 2014 May;69(5):1162–1176.
   PubMed Web of Science ®Google Scholar
• Lu M, Yan H, Yu C, et al. Proton pump inhibitors act synergistically with fluconazole against resistant Candida albicans. Sci Rep. 2020 Jan 16;10(1):498.
   PubMedGoogle Scholar
• Kapetas AJ, Abuhelwa AY, Sorich MJ, et al. Evidence-based guidelines for drug interaction studies: model-informed time course of intestinal and hepatic CYP3A4 inhibition by clarithromycin. AAPS J. 2021 Aug 31;23(5):104.
   PubMed Web of Science ®Google Scholar
• Calabresi L, Pazzucconi F, Ferrara S, et al. Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers. Pharmacol Res. 2004 May;49(5):493–499.
   PubMed Web of Science ®Google Scholar
• Saito M, Yasui-Furukori N, Uno T, et al. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. Br J Clin Pharmacol. 2005 Mar;59(3):302–309.
   PubMed Web of Science ®Google Scholar
• Cao S, Zhou G, Ou-Yang DS, et al. Pharmacokinetic interactions between ilaprazole and clarithromycin following ilaprazole, clarithromycin and amoxicillin triple therapy. Acta Pharmacol Sin. 2012 Aug;33(8):1095–1100.
   PubMed Web of Science ®Google Scholar
• Jin BH, Yoo BW, Park J, et al. Pharmacokinetic drug interaction and safety after coadministration of clarithromycin, amoxicillin, and ilaprazole: a randomised, open-label, one-way crossover, two parallel sequences study. Eur J Clin Pharmacol. 2018 Sep;74(9):1149–1157.
   PubMedGoogle Scholar
• Georgopoulos S, Papastergiou V. An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection. Expert Opin Pharmacother. 2021 Apr;22(6):729–741.
   PubMed Web of Science ®Google Scholar
• Lin YA, Wang H, Gu ZJ, et al. Effect of CYP2C19 gene polymorphisms on proton pump inhibitor, amoxicillin, and levofloxacin triple therapy for eradication of Helicobacter pylori. Med Sci Monit. 2017 Jun 3;23:2701–2707.
   PubMed Web of Science ®Google Scholar
• Soares GA, Pires DW, Pinto LA, et al. The influence of omeprazole on the dissolution processes of pH-dependent magnetic tablets assessed by pharmacomagnetography. Pharmaceutics. 2021 Aug 17; 13(8):1274.
   PubMedGoogle Scholar
• Offman E, Schobelock MJ, Brickl R, et al. Pharmacokinetics and pharmacodynamics of the antiplatelet combination aspirin (acetylsalicylic acid) plus extended-release dipyridamole are not altered by coadministration with the potent CYP2C19 inhibitor omeprazole. Am J Cardiovasc Drugs. 2013 Apr;13(2):113–120.
   PubMedGoogle Scholar
• Colombier MA, Molina JM. Doravirine: a review. Curr Opin HIV AIDS. 2018 Jul;13(4):308–314.
   PubMed Web of Science ®Google Scholar
• Khalilieh SG, Yee KL, Sanchez RI, et al. A study to evaluate doravirine pharmacokinetics when coadministered with acid-reducing agents. J Clin Pharmacol. 2019 Aug;59(8):1093–1098.
   PubMedGoogle Scholar
• Van Den Abeele J, Kostantini C, Barker R, et al. The effect of reduced gastric acid secretion on the gastrointestinal disposition of a ritonavir amorphous solid dispersion in fasted healthy volunteers: an in vivo - in vitro investigation. Eur J Pharm Sci. 2020 Aug;1(151):105377.
   Google Scholar
• Pohl O, Osterloh I, Lecomte V, et al. Changes in gastric pH and in pharmacokinetics of ulipristal acetate - a drug-drug interaction study using the proton pump inhibitor esomeprazole. Int J Clin Pharmacol Ther. 2013 Jan;51(1):26–33.
   PubMed Web of Science ®Google Scholar
• Reau N, Robertson MN, Feng HP, et al. Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: a pooled analysis of 1,322 patients with hepatitis C infection. Hepatol Commun. 2017 Oct 1;1(8):757–764.
   PubMedGoogle Scholar
• Trifiro G, Corrao S, Alacqua M, et al. Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources. Br J Clin Pharmacol. 2006 Nov;62(5):582–590.
   PubMedGoogle Scholar
• Flamm S, Reddy KR, Zadeikis N, et al. Efficacy and pharmacokinetics of glecaprevir and pibrentasvir with concurrent use of acid-reducing agents in patients with chronic HCV infection. Clin Gastroenterol Hepatol. 2019 Feb;17(3):527–535 e6.
   PubMedGoogle Scholar
• Tett S, Day R, Cutler D. Hydroxychloroquine relative bioavailability: within subject reproducibility. Br J Clin Pharmacol. 1996 Mar;41(3):244–246.
   PubMedGoogle Scholar
• Stoll F, Blank A, Mikus G, et al. Effect of pantoprazole on the absorption of hydroxychloroquinea a randomized drug-drug interaction trial in healthy adults. Clin Pharmacol Drug Dev. 2022 Feb;11(2):285–290.
   PubMedGoogle Scholar
• Jallouli M, Galicier L, Zahr N, et al. Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. Arthritis Rheumatol. 2015 May;67(8):2176–2184.
   PubMed Web of Science ®Google Scholar
• Dean L. Clopidogrel therapy and CYP2C19 genotype. In: Pratt VM, Scott SA, Pirmohamed M, et al., editors. Medical genetics summaries. Bethesda (MD): National Center for Biotechnology Information (US); 2012.
   Google Scholar
• Gilard M, Arnaud B, Le Gal G, et al. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost. 2006 Nov;4(11):2508–2509.
   PubMed Web of Science ®Google Scholar
• Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole clopidogrel aspirin) study. J Am Coll Cardiol. 2008 Jan 22;51(3):256–260.
   PubMed Web of Science ®Google Scholar
• Ho PM, Maddox TM, and Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009 Mar 4;301(9):937–944.
   PubMed Web of Science ®Google Scholar
• Muthiah MD, Zheng H, Chew NWS, et al. Outcomes of a multi-ethnic Asian population on combined treatment with clopidogrel and omeprazole in 12,440 patients. J Thromb Thrombolysis. 2021 Oct;52(3):925–933.
   PubMedGoogle Scholar
• Lau WC, Gurbel PA. The drug-drug interaction between proton pump inhibitors and clopidogrel. Cmaj. 2009 Mar 31;180(7):699–700.
   PubMedGoogle Scholar
• Moreira Dias L. Pantoprazole: a proton pump inhibitor. Clin Drug Investig. 2009;29(2):3–12.
   PubMedGoogle Scholar
• Melloni C, Washam JB, Jones WS, et al. Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review. Circ Cardiovasc Qual Outcomes. 2015 Jan;8(1):47–55.
   PubMed Web of Science ®Google Scholar
• Demcsák A, Lantos T, Bálint ER, et al. PPIs are not responsible for elevating cardiovascular risk in patients on clopidogrel-a systematic review and meta-analysis. Front Physiol. 2018;9:1550.
   PubMedGoogle Scholar
• Farhat N, Fortin Y, Haddad N, et al. Systematic review and meta-analysis of adverse cardiovascular events associated with proton pump inhibitors used alone or in combination with antiplatelet agents. Crit Rev Toxicol. 2019 Mar;49(3):215–261.
   PubMedGoogle Scholar
• Lin SF, Lin PC, Chang CC, et al. Investigation of the interaction between proton pump inhibitors and clopidogrel using VerifyNow P2Y12 assay. Medicine (Baltimore). 2020 Dec 11;99(50):e23695.
   PubMedGoogle Scholar
• Leonard CE, Bilker WB, Brensinger CM, et al. Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors. Stroke. 2015 Mar;46(3):722–731.
   PubMedGoogle Scholar
• Shi W, Ni L, Yang J, et al. The clinical impact of proton pump inhibitors when co-administered with dual antiplatelet therapy in patients having acute myocardial infarction with low risk of gastrointestinal bleeding: insights from the China acute myocardial infarction registry. Front Cardiovasc Med. 2021;8:685072.
   PubMedGoogle Scholar
• Shi WC, Gao SD, Yang JG, et al. Impact of proton pump inhibitors on clinical outcomes in patients after acute myocardial infarction: a propensity score analysis from China Acute Myocardial Infarction (CAMI) registry. J Geriatr Cardiol. 2020 Nov 28;17(11):659–665.
   PubMedGoogle Scholar
• Kim MS, Song HJ, Lee J, et al. Effectiveness and safety of clopidogrel co-administered with statins and proton pump inhibitors: a Korean national health insurance database study. Clin Pharmacol Ther. 2019 Jul;106(1):182–194.
   PubMedGoogle Scholar
• Bang CS, Joo MK, Kim BW, et al. The role of acid suppressants in the prevention of anticoagulant-related gastrointestinal bleeding: a systematic review and meta-analysis. Gut Liver. 2020 Jan 15;14(1):57–66.
   PubMedGoogle Scholar
• Cole JA, Taylor JS, Hangartner TN, et al. Reducing selection bias in case-control studies from rare disease registries. Orphanet J Rare Dis. 2011 Sep;12(6):61.
   Google Scholar
• Gadzhanova SRE. Co-prescribing of warfarin with statins and proton pump inhibitors in elderly Australians. Adv Pharmacoepidemiol Drug Saf. 2014;3:3.
   Google Scholar
• Wang M, Zeraatkar D, Obeda M, et al. Drug-drug interactions with warfarin: a systematic review and meta-analysis. Br J Clin Pharmacol. 2021 Nov;87(11):4051–4100.
   PubMedGoogle Scholar
• Bertram V, Yeo K, Anoopkumar-Dukie S, et al. Proton pump inhibitors co-prescribed with warfarin reduce warfarin control as measured by time in therapeutic range. Int J Clin Pract. 2019 Nov;73(11):e13382.
   PubMedGoogle Scholar
• Kuwayama T, Osanai H, Ajioka M, et al. Influence of proton pump inhibitors on blood dabigatran concentrations in Japanese patients with non-valvular atrial fibrillation. J Arrhythm. 2017 Dec;33(6):619–623.
   PubMedGoogle Scholar
• Bolek T, Samos M, Stanciakova L, et al. The impact of proton pump inhibition on dabigatran levels in patients with atrial fibrillation. Am J Ther. 2019 May;26(3):e308–e313.
   PubMed Web of Science ®Google Scholar
• Harada A, Ikushima I, Haranaka M, et al. Bioequivalence of a newly developed dabigatran etexilate tablet versus the commercial capsule and impact of rabeprazole-induced elevated gastric ph on exposure in healthy subjects. Am J Cardiovasc Drugs. 2020 Jun;20(3):249–258.
   PubMed Web of Science ®Google Scholar
• Schnierer M, Samos M, Bolek T, et al. The effect of proton pump inhibitor withdrawal on dabigatran etexilate plasma levels in patients with atrial fibrillation: a washout study. J Cardiovasc Pharmacol. 2020 Apr;75(4):333–335.
   PubMed Web of Science ®Google Scholar
• Ray WA, Chung CP, Murray KT, et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. Jama. 2018 Dec 4;320(21):2221–2230.
   PubMed Web of Science ®Google Scholar
• Chan EW, Lau WC, Leung WK, et al. Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: a population-based study. Gastroenterology. 2015 Sep;149(3):586–95.e3.
   PubMedGoogle Scholar
• Nies AT, Hofmann U, Resch C, et al. Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs). PLoS One. 2011;6(7):e22163.
   PubMed Web of Science ®Google Scholar
• Kim A, Chung I, Yoon SH, et al. Effects of proton pump inhibitors on metformin pharmacokinetics and pharmacodynamics. Drug Metab Dispos. 2014 Jul;42(7):1174–1179.
   PubMedGoogle Scholar
• Flory J, Haynes K, Leonard CE, et al. Proton pump inhibitors do not impair the effectiveness of metformin in patients with diabetes. Br J Clin Pharmacol. 2015 Feb;79(2):330–336.
   PubMed Web of Science ®Google Scholar
• Al-Bachaji IN, Al-Buhadiliy AK, Al-Kuraishy HM, et al. Proton pump inhibitors regulate metabolic profile and glycaemic indices in patients with type 2 diabetes mellitus: a rising dawn of a new therapeutic concept. J Pak Med Assoc. 2019 Aug;69(8):S31–S35.
   PubMedGoogle Scholar
• Peng CC, Tu YK, Lee GY, et al. Effects of proton pump inhibitors on glycemic control and incident diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2021 Oct 21;106(11):3354–3366.
   PubMedGoogle Scholar
• Ginanneschi F, Volpi N, Giannini F, et al. Rhabdomyolysis in an elderly multitreated patient: multiple drug interactions after statin withdrawal. J Neurol Sci. 2014 Jan 15;336(1–2):284–287.
   PubMed Web of Science ®Google Scholar
• Kashour T, Al-Tannir M, Bahamid R. Changing prescription pattern of omeprazole among patients receiving clopidogrel. Int Heart J. 2014;55(2):93–95.
   PubMedGoogle Scholar
• Baekdal TA, Breitschaft A, Navarria A, et al. A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide. Expert Opin Drug Metab Toxicol. 2018 Aug;14(8):869–877.
   PubMed Web of Science ®Google Scholar
• Raoul JL, Guerin-Charbonnel C, Edeline J, et al. Prevalence of proton pump inhibitor use among patients with cancer. JAMA Network Open. 2021 Jun 1;4(6):e2113739.
   PubMedGoogle Scholar
• Budha NR, Frymoyer A, Smelick GS, et al. Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? Clin Pharmacol Ther. 2012 Aug;92(2):203–213.
   PubMed Web of Science ®Google Scholar
• Peters S, Zimmermann S, Adjei AA. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions. Cancer Treat Rev. 2014 Sep;40(8):917–926.
   PubMed Web of Science ®Google Scholar
• van Leeuwen RW, van Gelder T, Mathijssen RH, et al. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol. 2014 Jul;15(8):e315–26.
   PubMed Web of Science ®Google Scholar
• Veerman GDM, Hussaarts K, Peric R, et al. Influence of cow’s milk and esomeprazole on the absorption of erlotinib: a randomized, crossover pharmacokinetic study in lung cancer patients. Clin Pharmacokinet. 2021 Jan;60(1):69–77.
   PubMedGoogle Scholar
• Ohgami M, Kaburagi T, Kurosawa A, et al. Effects of proton pump inhibitor coadministration on the plasma concentration of erlotinib in patients with non-small cell lung cancer. Ther Drug Monit. 2018 Dec;40(6):699–704.
   PubMedGoogle Scholar
• Yokota H, Sato K, Okuda Y, et al. Effects of histamine 2-receptor antagonists and proton pump inhibitors on the pharmacokinetics of gefitinib in patients with non-small-cell lung cancer. Clin Lung Cancer. 2017 Nov;18(6):e433–e439.
   PubMed Web of Science ®Google Scholar
• Song HJ, Rhew K, Lee YJ, et al. Acid-suppressive agents and survival outcomes in patients with cancer: a systematic review and meta-analysis. Int J Clin Oncol. 2021 Jan;26(1):34–50.
   PubMedGoogle Scholar
• Sharma M, Holmes HM, Mehta HB, et al. The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer. 2019 Apr 1;125(7):1155–1162.
   PubMed Web of Science ®Google Scholar
• Sim W, Jain SR, Lim WH, et al. Interactions between epidermal growth factor receptor tyrosine kinase inhibitors and proton-pump inhibitors/histamine type-2 receptor antagonists in non-small cell lung cancer: a systematic review and meta-analysis. Transl Lung Cancer Res. 2021 Aug;10(8):3567–3581.
   PubMedGoogle Scholar
• Lalani AA, McKay RR, Lin X, et al. Proton pump inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2017 Dec;15(6):724–732.
   PubMed Web of Science ®Google Scholar
• Ha VH, Ngo M, Chu MP, et al. Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer? J Oncol Pharm Pract. 2015 Jun;21(3):194–200.
   PubMed Web of Science ®Google Scholar
• Mir O, Touati N, Lia M, et al. Impact of concomitant administration of gastric acid-suppressive agents and pazopanib on outcomes in soft-tissue sarcoma patients treated within the EORTC 62043/62072 trials. Clin Cancer Res. 2019 Mar 1;25(5):1479–1485.
   PubMedGoogle Scholar
• de Man FM, Hussaarts K, de With M, et al. Influence of the proton pump inhibitor esomeprazole on the bioavailability of regorafenib: a randomized crossover pharmacokinetic study. Clin Pharmacol Ther. 2019 Jun;105(6):1456–1461.
   PubMedGoogle Scholar
• Van De Sijpe G, Beuselinck B, Van Nieuwenhuyse T, et al. Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma. Eur J Clin Pharmacol. 2020 Sep;76(9):1273–1280.
   PubMedGoogle Scholar
• Krens SD, Lubberman FJE, van Egmond M, et al. The impact of a 1-hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure. Int J Cancer. 2021 Jun 1;148(11):2799–2806.
   PubMedGoogle Scholar
• Yin OQ, Giles FJ, Baccarani M, et al. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemother Pharmacol. 2012 Aug;70(2):345–350.
   PubMed Web of Science ®Google Scholar
• Koutake Y, Taniguchi J, Yasumori N, et al. Influence of proton pump inhibitors and H2-receptor antagonists on the efficacy and safety of dasatinib in chronic myeloid leukemia patients. Int J Hematol. 2020 Jun;111(6):826–832.
   PubMedGoogle Scholar
• Hussaarts K, Veerman GDM, Jansman FGA, et al. Clinically relevant drug interactions with multikinase inhibitors: a review. Ther Adv Med Oncol. 2019;11:1758835918818347.
   Web of Science ®Google Scholar
• Rassy E, Cerbone L, Auclin E, et al. The effect of concomitant proton pump inhibitor and cabozantinib on the outcomes of patients with metastatic renal cell carcinoma. Oncologist. 2021 May;26(5):389–396.
   PubMedGoogle Scholar
• Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018 Jan 5;359(6371):97–103.
   PubMed Web of Science ®Google Scholar
• Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013 Nov 22;342(6161):971–976.
   PubMed Web of Science ®Google Scholar
• Trifan A, Stanciu C, Girleanu I, et al. Proton pump inhibitors therapy and risk of Clostridium difficile infection: systematic review and meta-analysis. World J Gastroenterol. 2017 Sep 21;23(35):6500–6515.
   PubMed Web of Science ®Google Scholar
• Weersma RK, Zhernakova A, Fu J. Interaction between drugs and the gut microbiome. Gut. 2020 Aug;69(8):1510–1519.
   PubMed Web of Science ®Google Scholar
• Kato K, Mizuno T, Koseki T, et al. Concomitant proton pump inhibitors and immune checkpoint inhibitors increase nephritis frequency. Vivo. 2021 Sep–Oct;35(5):2831–2840.
   PubMed Web of Science ®Google Scholar
• Chalabi M, Cardona A, Nagarkar DR, et al. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Ann Oncol. 2020 Apr;31(4):525–531.
   PubMed Web of Science ®Google Scholar